Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 18/20 | 0.91 |
| ▸ | NSD2 | O96028 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | BID | P55957 | 1/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.80 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.80 |
| ▸ | BAD | Q92934 | 1/20 | 0.80 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.80 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313804 | 1.00 | BCL2 (0.91) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30313900 | 0.96 | BCL2 (0.84) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1702858 | 0.96 | BCL2 (0.84) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1701595 | 0.95 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30314066 | 0.95 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1699889 | 0.95 | BCL2 (0.84) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30314143 | 0.95 | BCL2 (0.84) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1699846 | 0.95 | BCL2 (0.83) | BCL2 | |
| SCHEMBL31344631 | 0.95 | BCL2 (0.83) | BCL2 | |
| SCHEMBL1700169 | 0.94 | BCL2 (0.82) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | claimed |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2020-07-16 | — | — | US | claimed |
| CN-105664164-B | Methods of treatment using selective BCL-2 inhibitors | 艾伯维巴哈马有限公司 | 2020-05-05 | — | — | CN | claimed |
| US-20190275051-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. | 2019-09-12 | — | — | US | claimed |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2018-12-27 | — | — | US | claimed |
| EP-3028702-B1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-09-12 | — | — | EP | claimed |
| EP-2632436-B1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2018-08-29 | — | — | EP | claimed |
| US-9872861-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2018-01-23 | — | — | US | claimed |
| EP-3219308-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2017-09-20 | — | — | EP | claimed |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2017-08-17 | — | — | US | claimed |
| WO-2012071374-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-31 | — | — | WO | claimed |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | claimed |
| WO-2012058392-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | WO | claimed |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | claimed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | claimed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | claimed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885NSD2 2463/4885ADORA3 4652/4885 |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885NSD2 1465/4885ADORA3 4820/4885 |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | BCL2 1/4885NSD2 2551/4885ADORA3 4740/4885 |
| US-20190275051-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | BCL2 1/4885NSD2 1660/4885ADORA3 4782/4885 |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885NSD2 1478/4885ADORA3 4828/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885NSD2 2195/4885ADORA3 4585/4885 |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885NSD2 1324/4885ADORA3 4797/4885 |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885NSD2 1465/4885ADORA3 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.